Truvian Sciences today announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company’s Easy Check COVID-19 IgM/IgGTM antibody test. Truvian’s Easy Check test is being produced at mass scale at a US based manufacturing facility and will be available to healthcare practitioners immediately.
Category: BioSpace
Hours before the U.S. FDA granted Emergency Use Authorization to a rapid SARS-CoV-2 point-of-care diagnostic, Jeff Hawkins, CEO of Truvian Sciences, noted that in all of the industry response to the pandemic, approval of such a device was still missing
Despite all her failings and unethical behavior as head of Theranos, Elizabeth Holmes got one thing right – and that was her early realization that consumers would want access to a personalized diagnostics tool